TORONTO and GLIL YAM, Israel — IM Cannabis Corp., an international medical cannabis company, has applied for a voluntary delisting of its common shares from the Canadian Securities Exchange (CSE). The delisting from the CSE will not affect the Company’s listing on NASDAQ and its shares will continue trading on the NASDAQ.
The company is entertaining potential transactions that, if completed while the company is listed on the CSE, would require the company to incur unnecessary burdensome costs, approvals and delay. The company believes that the trading volume of its shares on the CSE no longer justifies the expenses, administrative efforts, and regulatory burdens required to maintain a dual listing. The company also believes that delisting from the CSE will create a central marketplace for its shares on the Nasdaq and ultimately benefit the long-term liquidity and shareholder value of the company.
The company is grateful to the CSE for providing its initial opportunity to access public markets. It is expected, subject to approval from the CSE, that the close of business on Monday, June 2, 2025, will be the final trading day for IMC on the CSE.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The company leverages a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain.
The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The company also operates medical cannabis retail pharmacies, online platforms and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Related Articles:
